In addition to variances in surgical and radiation approaches, the chemotherapeutic treatment of each breast cancer subtype also differs; hormone-positive subtypes typically respond to endocrine therapy, HER2-positive subtypes require HER2-targeted therapy, and TNBC relies on cytotoxic agents [3]. This evidence concerns the gene ERBB2 and breast carcinoma.